FRET-Based Sorting of Live Cells Reveals Shifted Balance between PLK1 and CDK1 Activities During Checkpoint Recovery.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
19 09 2020
Historique:
received: 21 08 2020
revised: 11 09 2020
accepted: 14 09 2020
entrez: 23 9 2020
pubmed: 24 9 2020
medline: 25 3 2021
Statut: epublish

Résumé

Cells recovering from the G2/M DNA damage checkpoint rely more on Aurora A-PLK1 signaling than cells progressing through an unperturbed G2 phase, but the reason for this discrepancy is not known. Here, we devised a method based on a FRET reporter for PLK1 activity to sort cells in distinct populations within G2 phase. We employed mass spectroscopy to characterize changes in protein levels through an unperturbed G2 phase and validated that ATAD2 levels decrease in a proteasome-dependent manner. Comparing unperturbed cells with cells recovering from DNA damage, we note that at similar PLK1 activities, recovering cells contain higher levels of Cyclin B1 and increased phosphorylation of CDK1 targets. The increased Cyclin B1 levels are due to continuous Cyclin B1 production during a DNA damage response and are sustained until mitosis. Whereas partial inhibition of PLK1 suppresses mitotic entry more efficiently when cells recover from a checkpoint, partial inhibition of CDK1 suppresses mitotic entry more efficiently in unperturbed cells. Our findings provide a resource for proteome changes during G2 phase, show that the mitotic entry network is rewired during a DNA damage response, and suggest that the bottleneck for mitotic entry shifts from CDK1 to PLK1 after DNA damage.

Identifiants

pubmed: 32961751
pii: cells9092126
doi: 10.3390/cells9092126
pmc: PMC7564076
pii:
doi:

Substances chimiques

CCNB1 protein, human 0
Cell Cycle Proteins 0
Cyclin B1 0
DNA-Binding Proteins 0
Proto-Oncogene Proteins 0
TP53BP1 protein, human 0
Tumor Suppressor p53-Binding Protein 1 0
Zinostatin 9014-02-2
AURKA protein, human EC 2.7.11.1
Aurora Kinase A EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
CDC2 Protein Kinase EC 2.7.11.22
CDK1 protein, human EC 2.7.11.22
ATAD2 protein, human EC 3.6.1.3
ATPases Associated with Diverse Cellular Activities EC 3.6.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Cell Biol. 2019 Dec 2;218(12):3892-3902
pubmed: 31712253
Mol Cell. 2013 Nov 21;52(4):574-82
pubmed: 24120665
J Cell Biol. 2007 Mar 12;176(6):749-55
pubmed: 17353355
Mol Cell Biol. 2008 May;28(9):3076-87
pubmed: 18285455
Nat Commun. 2014 Jun 04;5:4048
pubmed: 24893992
Mol Cell. 2004 Sep 10;15(5):799-811
pubmed: 15350223
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
PLoS One. 2017 Dec 11;12(12):e0188772
pubmed: 29228002
EMBO J. 2017 Jul 14;36(14):2161-2176
pubmed: 28607002
FEBS Lett. 2019 Oct;593(20):2805-2816
pubmed: 31566708
Nat Cell Biol. 2018 Jan;20(1):92-103
pubmed: 29255170
PLoS Biol. 2010 Jan 26;8(1):e1000287
pubmed: 20126263
Nat Rev Mol Cell Biol. 2013 Aug;14(8):518-28
pubmed: 23877564
J Cell Biol. 2019 Jul 1;218(7):2169-2184
pubmed: 31186278
Mol Cell Proteomics. 2013 Aug;12(8):2324-31
pubmed: 23589346
Elife. 2019 May 28;8:
pubmed: 31134895
Science. 2018 Aug 24;361(6404):806-810
pubmed: 30139873
Methods Mol Biol. 2016;1342:173-83
pubmed: 26254923
Curr Biol. 2006 Oct 10;16(19):1950-5
pubmed: 16934469
Nat Cell Biol. 2008 Sep;10(9):1076-82
pubmed: 19160488
Mol Cell. 2006 Aug 4;23(3):307-18
pubmed: 16885021
J Cell Sci. 2015 Feb 15;128(4):607-20
pubmed: 25609713
Mol Cell. 2014 Mar 6;53(5):843-53
pubmed: 24582498
J Mol Cell Biol. 2019 Aug 19;11(8):703-718
pubmed: 30452682
Anticancer Res. 2010 Dec;30(12):4973-85
pubmed: 21187478
Mol Cell. 2018 Jul 5;71(1):117-128.e3
pubmed: 30008317
Curr Biol. 2002 Oct 29;12(21):1797-806
pubmed: 12419179
Nature. 2008 Sep 4;455(7209):119-23
pubmed: 18615013
Cell Struct Funct. 2019 Nov 2;44(2):153-169
pubmed: 30905922
Elife. 2017 Oct 20;6:
pubmed: 29052541
Biosens Bioelectron. 2019 Aug 1;138:111314
pubmed: 31096114
FEBS J. 2019 Dec;286(23):4650-4656
pubmed: 31446671
Mol Cell. 2006 Aug 4;23(3):319-29
pubmed: 16885022
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Biol Chem. 2019 Oct 4;294(40):14814-14822
pubmed: 31434714
Science. 1997 Dec 12;278(5345):1957-60
pubmed: 9395400
Cell Rep. 2017 Jun 6;19(10):2060-2073
pubmed: 28591578
Cell Syst. 2017 Jul 26;5(1):72-81.e4
pubmed: 28750200

Auteurs

Lorenzo Lafranchi (L)

Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Erik Müllers (E)

Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Dorothea Rutishauser (D)

Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Science for Life Laboratory, SE-171 65 Stockholm, Sweden.

Arne Lindqvist (A)

Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH